A. V. Elonakov

1.4k total citations
11 papers, 20 citations indexed

About

A. V. Elonakov is a scholar working on Rheumatology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. V. Elonakov has authored 11 papers receiving a total of 20 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 5 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. V. Elonakov's work include Rheumatoid Arthritis Research and Therapies (4 papers), Vasculitis and related conditions (3 papers) and Systemic Lupus Erythematosus Research (3 papers). A. V. Elonakov is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (4 papers), Vasculitis and related conditions (3 papers) and Systemic Lupus Erythematosus Research (3 papers). A. V. Elonakov collaborates with scholars based in Russia, United States and Tajikistan. A. V. Elonakov's co-authors include Е Н Александрова, E L Nasonov, Z S Alekberova, Sergey Moiseev, Pavel Novikov, Е. Л. Лучихина, Maria Sokolova, Д. Е. Каратеев, Л А Калашникова and А. В. Смирнов and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the Rheumatic Diseases and Rheumatology Science and Practice.

In The Last Decade

A. V. Elonakov

9 papers receiving 17 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. V. Elonakov Russia	3	13	7	6	6	4	11	20
Jeffrey M. Zink United States	3	12 0.9×	4 0.6×	2 0.3×	16 2.7×	6 1.5×	4	24
Akpabio Akpabio Nigeria	3	10 0.8×	4 0.6×	5 0.8×	2 0.3×	1 0.3×	10	18
Margit Zeher Hungary	4	13 1.0×	6 0.9×	7 1.2×		2 0.5×	5	27
Elena Ávalos Spain	4	10 0.8×	4 0.6×	4 0.7×		2 0.5×	13	34
Tímea Baló Hungary	3	5 0.4×	2 0.3×	2 0.3×	6 1.0×		3	19
Yasuyoshi Kusanagi Japan	3	7 0.5×	6 0.9×	4 0.7×		1 0.3×	5	17
Amin Dehghan Iran	3	3 0.2×	3 0.4×	2 0.3×	7 1.2×	2 0.5×	11	25
I Orbán Hungary	3	9 0.7×	5 0.7×	3 0.5×			11	16
Ia Topuria United States	3	6 0.5×	6 0.9×	6 1.0×			7	21
M. J. Brown	3	11 0.8×	6 0.9×			3 0.8×	3	24

Countries citing papers authored by A. V. Elonakov

Since Specialization

Citations

This map shows the geographic impact of A. V. Elonakov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. V. Elonakov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. V. Elonakov more than expected).

Fields of papers citing papers by A. V. Elonakov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. V. Elonakov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. V. Elonakov. The network helps show where A. V. Elonakov may publish in the future.

Co-authorship network of co-authors of A. V. Elonakov

This figure shows the co-authorship network connecting the top 25 collaborators of A. V. Elonakov. A scholar is included among the top collaborators of A. V. Elonakov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. V. Elonakov. A. V. Elonakov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Каратеев, Д. Е., et al.. (2017). Efficiency of tocilizumab therapy for an exacerbation of systemic lupus erythematosus: A case report and a review of literature. Modern Rheumatology Journal. 11(3). 85–90. 1 indexed citations

Александрова, Е Н, et al.. (2017). THE TIME COURSE OF CHANGES IN B LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING THERAPY WITH BIOLOGICAL AGENTS. Rheumatology Science and Practice. 55(3). 252–260. 4 indexed citations

Эрдес, Ш. Ф., et al.. (2016). CLINICAL CHARACTERISTICS OF ANKYLOSING SPONDYLITIS IN REAL PRACTICE IN RUSSIA: RESULTS OF THE CROSS-SECTIONAL NON-INTERVENTIONAL TRIAL EPICA2. Rheumatology Science and Practice. 54(1S). 10–14. 5 indexed citations

Sokolova, Maria, et al.. (2016). AB1027 Use of Biologic Dmards in Russian Patients with Rheumatic Diseases: Analysis of The 6 Year-Experience of The Moscow Regional Research and Clinical Institute. Annals of the Rheumatic Diseases. 75. 1253–1253.

Novikov, Pavel, et al.. (2015). THU0293 Safety and Efficacy of Short-Term Treatment with Tocilizumab in Patients with Refractory Takayasu Arteritis. Annals of the Rheumatic Diseases. 74. 302–302. 3 indexed citations

Elonakov, A. V., et al.. (2012). Comparative efficacy of infliximab and adalimumab in patients with ankylosing spondylitis. SHILAP Revista de lepidopterología. 0(2). 25–25.

Nasonov, E L, et al.. (2010). The efficiency and safety of tocilizumab in rheumatoid arthritis(intermediate results of a Russian multicenter study). Rheumatology Science and Practice. 0(2). 21–21. 1 indexed citations

Elonakov, A. V., et al.. (2008). Opyt mnogoletnego primeneniya sandimmuna neorala u patsientov s bolezn'yu Bekhcheta (obzor literatury i sobstvennye nablyudeniya). Modern Rheumatology Journal. 0(2). 57–57. 1 indexed citations

Alekberova, Z S, et al.. (2008). [Behcet's disease and joint affection].. PubMed. 80(5). 56–8. 2 indexed citations

10.

Калашникова, Л А, et al.. (2007). Neurological signs of Behcet’s disease. Rheumatology Science and Practice. 0(3). 109–109. 1 indexed citations

11.

Alekberova, Z S, et al.. (2005). [Vascular symptoms of Behcet's disease].. PubMed. 77(5). 39–41. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact